NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said today that it has acquired privately held antibody maker Affinity BioReagents for an undisclosed amount.
 
Golden, Colo.-based Affinity makes monoclonal and polyclonal antibodies, peptides, proteins, and other reagents. The firm, which offers more than 35,000 reagents, also provides recombinant proteins and custom antibody-production services, said Thermo Fisher.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.